Post by
RelevantStock on Dec 08, 2020 12:35pm
Great News Recap
That was a great CC, forget what the bashers say, here's a recap of the facts. It was all great news, nothing was negative:
- Aristotle to be launched in Q1 2021, with the current covid clients (so probably Mercer included) and with healthcare partners (Tripp mentionned cancer clinics)
- Revenue trajectory remains the same for current Q4 - so it's still rising. Covid revenues should continue to flow in probably untill 2022 according to the company projections
- The company has doubled in size in staffing, the lab will double in space during 2021
- Covid testing is going well, Barbados only has 2700 travelers going in and out of the country every week. We are testing for Barbados, Hawaii, Arizona and China, and our good reputation brings us in conversation with other governments too.
- A quick mention of Stagezero's fair valuation was made. Competitors were sold at 8 billions (Grail) and 2.15 billions (Thrive).
- Stagezero is dozen of years ahead the competition in their cancer testing technology according to the company
Those are the facts, whatever bashers say they are not stating facts or they are distorting the reality. Good luck to all!
Comment by
capebretongirl on Dec 08, 2020 1:33pm
Colonsentry was approved on the Sentinel principle so FDA approval should be relatively accelerated as Aristotle is on the same platform. Also, this is not a drug, its a detection mechanism which can't be harmful to the public. FDA approval will also provide a bg catalyst to the sp the day its announced.